By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



540 – 1385 West 8th Avenue

Vancouver  British Columbia  V6H 3V9  Canada
Phone: 604-678-1388 Fax: 604-737-7077



Start Up

Company News
Zymeworks And Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement And Bi-Specific Antibody Collaboration 9/28/2016 8:10:51 AM
Zymeworks Doses First Patient In Phase I Trial Of ZW25, A Novel Bi-Specific Antibody For The Treatment Of HER2-Expressing Cancers 9/15/2016 11:40:33 AM
Zymeworks Receives FDA Acceptance Of IND Application For ZW25, A Novel Bi-Specific Antibody, For The Treatment Of HER2-Expressing Cancers 8/18/2016 9:29:49 AM
Zymeworks’ ZW25 And ZW33 Granted Orphan Drug Designation for Ovarian Cancer By U.S. FDA 8/18/2016 9:27:53 AM
Zymeworks And Innovative Targeting Solutions Enter Collaboration And License Agreement To Advance Biotherapeutics Research And Development 8/11/2016 11:36:16 AM
Zymeworks Names Diana Hausman, M.D. Chief Medical Officer 4/26/2016 11:39:34 AM
GlaxoSmithKline (GSK) Nails Down Access to Zymeworks' Azymetric Drug Discovery Platform in Deal Worth $908 Million 4/26/2016 5:51:42 AM
Zymeworks Completes Acquisition Of Kairos Therapeutics Creating A Leader In Biologics Drug Discovery And Development 3/22/2016 11:06:36 AM
Zymeworks Announces The Successful Achievement Of A Milestone With Eli Lilly (LLY) In Bi-Specific Antibody Therapeutics Collaboration 1/19/2016 10:12:33 AM
Zymeworks And Kairos Therapeutics Enter Into Strategic Partnership And Optional Merger Agreement To Develop Antibody Drug Conjugates And Bi-Specific Antibodies 1/8/2016 11:29:45 AM